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In combination with microspotting, whole-blood microfluidics can pro-vide high-throughput information on multiple platelet functions inthrombus formation. Based on assessment of the inter- and intra-subject
variability in parameters of microspot-based thrombus formation, we
aimed to determine the platelet factors contributing to this variation. Blood
samples from 94 genotyped healthy subjects were analyzed for convention-
al platelet phenotyping: i.e. hematologic parameters, platelet glycoprotein
(GP) expression levels and activation markers (24 parameters). Furthermore,
platelets were activated by ADP, CRP-XL or TRAP. Parallel samples were
investigated for whole-blood thrombus formation (6 microspots, providing
48 parameters of adhesion, aggregation and activation). Microspots trig-
gered platelet activation through GP Ib-V-IX, GPVI, CLEC-2 and integrins.
For most thrombus parameters, inter-subject variation was 2-4 times higher
than the intra-subject variation. Principal component analyses indicated
coherence between the majority of parameters for the GPVI-dependent
microspots, partly linked to hematologic parameters, and glycoprotein
expression levels. Prediction models identified parameters per microspot
that were linked to variation in agonist-induced αIIbb3 activation and secre-
tion. Common sequence variation of GP6 and FCER1G, associated with
GPVI-induced αIIbb3 activation and secretion, affected parameters of GPVI-
and CLEC-2-dependent thrombus formation. Subsequent analysis of blood
samples from patients with Glanzmann thrombasthenia or storage pool
disease revealed thrombus signatures of aggregation-dependent parameters
that were subject-dependent, but not linked to GPVI activity. Taken togeth-
er, this high-throughput elucidation of thrombus formation revealed pat-
terns of inter-subject differences in platelet function, which were partly
related to GPVI-induced activation and common genetic variance linked to
GPVI, but also included a distinct platelet aggregation component.
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ABSTRACT
Introduction
Whole-blood-based microfluidics methods, measuring
thrombus formation under flow, are increasingly used as
proxy measurements for in vivo models of thrombosis.
Such flow assays provide valuable mechanistic informa-
tion on the consequences of loss-of-function or gain-of-
function mutations of key platelet signaling proteins for
arterial thrombosis and hemostasis.1-4 Until recently, colla-
gen-coated surfaces were used for such measurements, so
as to approximate common collagen-dependent models of
arterial thrombosis in vivo.5,6 Recently, we showed that by
using multiple, microspotted surfaces this method can be
extended to multiparameter measurements of thrombus
formation,7 thus elucidating platelet dysfunction in
patients with a range of bleeding diatheses.7-9
Commonly, detection of an heritable or acquired
platelet function impairment is made by conventional
approaches, such as light transmission aggregometry,10, 11
flow cytometry,12 and the PFA-100.13 However, such tests
are limited by a low throughput and requirement of rela-
tively large volumes of blood, if multiple agonists at vari-
ous concentrations need to be tested. These limitations
can be overcome by higher-throughput, well-plate-based
tests of platelet aggregation or flow cytometric analysis.14,15
For the multiparameter measurement of thrombus forma-
tion, however, still little is known about the detection
capability to identify (small differences in) platelet pheno-
types in healthy subjects and groups of patients.
Two recent whole genome association studies have
identified over 640 independent single nucleotide variants
that are associated with quantitative platelet traits (count,
mean volume, distribution width of mean volume, and
mass or crit).16,17 Several of the variants appeared to be
linked to alterations in platelet activation tendency, in par-
ticular by using flow cytometric assessment of agonist-
induced integrin αIIbb3 activation and P-selectin expression
(measuring platelet secretion) in the genotyped individu-
als. Detailed studies revealed single nucleotide variants
which associated with altered platelet expression levels of
the collagen receptor, glycoprotein (GP)VI, and with
altered GPVI-induced activation responses.18-20
In the present study we aimed to evaluate, in a cohort
of genetically defined healthy subjects, the underlying rea-
sons of inter-individual variability in a microspot-based
multiparameter assay of thrombus formation. The results
were therefore related to a set of 24 other variables,
including hematologic parameters, platelet glycoprotein
expression levels and platelet activation markers.
Prediction models were built to link specific variables.
Blood samples from patients with bleeding disorders were
used to interpret the observed relations.
Methods
A detailed description of the methods is available in the Online
Supplement.
Blood donors and blood collection
Studies were approved by the Maastricht University Medical
Center Ethics Committee and the Cambridge East Research Ethics
Committee (Genetic analysis of platelets in healthy individuals,
REC ref 10/H0304/65). Healthy subjects (laboratory population) in
cohort 1 (n=10) donated three blood samples at 2- to 4-week inter-
vals. Genotyped healthy subjects (cohort 2, n=94) were analyzed
in a period of 2 weeks. These subjects were registered in the
National Institute for Health Research (NIHR) BioResource
(Unicorn-2 study). Genotyping of subjects in cohort 2 was per-
formed as described elsewhere.20 The subjects’ demographics are
indicated in Online Supplementary Table S1.
Included patients had confirmed Glanzmann thrombasthenia:
GT1: ITGA2B c.[2943G>A], [2943G>A], p. (=) (homozygous
splice mutation); GT2: ITGA2B c.213C>G; p.P71A, c.2051T>G,
p.L684A (compound heterozygous point mutations); GT3:
ITGA2B, c.621C>T; p.T176I (homozygous point mutation). Two
other patients had a confirmed quantitative delta-storage pool dis-
ease (reduced mepacrine capture/release): SPD1, SPD2. All
patients and the three day-control subjects had normal blood cell
counts (Online Supplementary Data File 1D).
High-throughput microfluidics
Glass coverslips were coated with three microspots of 0.5 μL (3
mm center-to-center distance) using a high-precision mold. Using
two sets of coverslips, a total of six different microspots (M1-6)
were applied for whole-blood perfusion (see Table 1).
Microfluidics assays were performed as described previously,7
with minor modifications. Details of the standard operating pro-
cedures are provided in the Online Supplement. Post-staining of
thrombi was performed with FITC-labeled anti-fibrinogen mono-
clonal antibody (1:100, Dako, F0111, Santa Clara, CA, USA),
Alexa Fluor (AF)568 annexin A5 (1:200, Molecular Probes), and
AF647 anti-CD62P monoclonal antibody (1:80, Biolegend,
London, UK). Representative brightfield and tri-color fluorescence
images were taken with an EVOS-FL microscope (Life
Technologies), equipped with GFP, RFP and Cy5 dichroic cubes
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Table 1. Overview of microspot surfaces (M) and parameters (P) in flow assays;
as well as platelet activation (A) markers in flow cytometry.
Microspot surface                                                        Platelet receptors involved
M1        collagen type I (VWF)*                                                          GPIb, GPVI, α2b1
M2        collagen type III (VWF)*                                                       GPIb, GPVI, α2b1
M3        VWF + laminin                                                                             GPIb + α6b1
M4        VWF-BP + GFOGER-(GPO)n                                               GPIb + GPVI, α2b1
M5        VWF-BP + rhodocytin                                                              GPIb + CLEC-2
M6        VWF-BP + fibrinogen                                                                GPIb + αIIbb3
Brightfield / Fluorescence parameters                  Range                 Normalized
P1         platelet surface area coverage (%SAC)         0 – 66.47                  0 – 10
P2         platelet aggregate (%SAC)                                0 – 47.84                  0 – 10
P3         thrombus morphological score                           0 – 5                      0 – 10
P4         thrombus multilayer score                                   0 – 3                      0 – 10
P5         thrombus contraction score                                 0 – 3                      0 – 10
P6         PS exposure (%SAC)                                          0 – 22.71                  0 – 10
P7         secretion (P-selectin positive, %SAC)           0 – 63.44                  0 – 10
P8         integrin αIIbb3 activation (%SAC)                     0 – 48.05                  0 – 10
Flow cytometry activation (A), secretion (Sec), integrin αIIbb3 activation (Int)
A1         unstimulated                                                    A1-Sec, A1-Int
A2         ADP-stimulated                                                A2-Sec, A2-Int
A3         CRP-XL-stimulated                                          A3-Sec, A3-Int
A4         TRAP-stimulated                                              A4-Sec, A4-Int
*(VWF), von Willebrand factor from plasma.
and an Olympus UPLSAPO 60x oil-immersion objective. Images
were analyzed for the parameters described in Table 1, using semi-
automated scripts written in Fiji. Test variability was 5-8%,
depending on the type of surface and parameter.
Platelet immunophenotyping and platelet activation by
flow cytometry
Platelet immunophenotyping and platelet activation were per-
formed basically as described previously.21 The platelet activation
parameters that were analyzed are presented in Table 1.
Results
Multiparameter assessment of whole-blood thrombus
formation on microspots under flow
High-throughput microfluidics has been used for in-
depth characterization of platelet dysfunction in patients
with bleeding disorders. The technique uses microspot-
coated flow chambers for multiparameter measurement
of thrombus formation during whole-blood perfusion at
defined wall-shear rates.7,9 In this study, we further stan-
dardized this method for inter-subject analysis of platelet
function, using blood samples from healthy subjects,
with results expected to represent the normal range
observed in a population. Procedures included (see also
the Online Supplement and de Witt et al.22): (i) microspot
coating using a high-precision mold; (ii) strictly controlled
conditions of blood drawing, anticoagulation and storage;
(iii) pulse-free blood perfusion through a Maastricht flow
chamber at a defined shear rate; (iv) defined time proto-
cols for rinsing, staining and capturing of brightfield and
fluorescence microscopic images; (v) pre-defined scripts
for consistent analysis of all image sets; (vi) a gallery of
exemplary images for the scoring of thrombus parame-
ters; and (vii) comparative analysis by trained personnel
performing flow runs and blind image analysis. Out of a
list of 52 different surfaces,7 we selected six microspots
(M1-6) to provide the most discriminative information on
small changes in thrombus formation. For each surface,
eight outcome parameters (P1-8) were defined, as indicat-
ed in Table 1.
Employing this standardized procedure, after whole-
blood perfusion over each of the microspots, representa-
tive images were taken to visualize and assess: platelet
adhesion (P1), platelet aggregation and thrombus mor-
phology (P2-5); platelet phosphatidylserine exposure, as a
marker of procoagulant activity (P6); P-selectin expres-
sion, to measure secretion (P7); and fibrinogen binding, to
report on integrin αIIbb3 activation (P8). Image sets for a
typical healthy control subject are given in Figure 1A.
Blood perfusion over microspot M1 (collagen type I)
resulted in the formation of large thrombi with contract-
ed aggregates of platelets, high in activation markers
(phosphatidylserine exposure, P-selectin expression, αIIbb3
activation), linked to a relatively high GPVI signal.7
Microspot M2 (collagen type III) produced smaller
platelet aggregates with less pronounced activation mark-
ers, corresponding to more limited GPVI signaling.
Microspot M3 [von Willebrand factor (VWF) + laminin]
gave a monolayer of platelets with P-selectin expression
and αIIbb3 activation, but essentially no phosphatidylser-
ine exposure, indicative of the primary adhesive role of
the laminin receptor, integrin α6b1. Microspot M4 con-
tained a combination of collagen-derived peptides [VWF-
BP + GFOGER-(GPO)n] giving similar thrombi as on colla-
gen type I. Microspot M5 (VWF-BP + rhodocytin) also
produced full aggregates with contraction of platelets
expressing activation markers. Microspot M6 (VWF-BP +
fibrinogen) triggered mainly platelet adhesion with the
scattered presence of small platelet aggregates, showing
limited P-selectin expression and αIIbb3 activation. The
observations for M1, M4 and M5 are in agreement with
the capability of GPVI and CLEC-2 adhesive surfaces to
support full thrombus formation in flow assays.7
To evaluate the performance of the standardized
method, we collected three different blood samples from
ten healthy donors (cohort 1), and determined the coeffi-
cients of variation for each of the parameters per
microspot (coated M1, M2 and M6). For the majority of
the parameters, intra-assay variability of duplicate meas-
urements was 5-8%. For microspots M1 and M2, the
median intra-individual coefficients of variation over the
three bleeds were 15% and 18%, respectively, which is
considered acceptable for whole-blood assays (Figure 1B).
For microspot M6, a higher median intra-individual coef-
ficient of variation of 37% was obtained, likely due to the
fact that parameter values on this ‘weak’ surface are low.
This initial analysis indicated that inter-individual coeffi-
cients of variation for the microspots were about twice as
high as the intra-individual coefficients of variation
(Online Supplementary Table S3).
High-throughput platelet phenotyping by 
multiparameter assessment of thrombus formation 
in combination with platelet count and platelet 
activation markers
Subsequently, thrombus formation was assessed on
microspots M1-6 with blood samples from 94 genotyped
healthy subjects from the NIHR BioResource (cohort 2, all
blood type O). Donors of either sex had a median age of
64 years (Online Supplementary Table S1). Using the same
microfluidics device, brightfield and fluorescence images
were recorded and analyzed for all eight parameters (P1-
8) per microspot. Comparison of the inter-individual
coefficients of variation for the 94 samples to the intra-
individual ones for a subset of ten of these samples indi-
cated, for the parameters of microspots M1-3, approxi-
mately 2-4 times higher inter-individual coefficients of
variation. This ratio was 2.5-1.5 times higher for the M4-
6 microspots (Figure 2A). Heat mapping of the normal-
ized values per parameter and microspot showed major
differences between the 94 blood samples (Figure 2B).
Taken together, these data indicated that a substantial
part of the measured values contained a subject-depen-
dent component.
For all 94 subjects, parallel measurements were per-
formed to assess: (i) hematologic parameters using a
Sysmex XN-1000 analyzer; (ii) expression levels of
platelet membrane proteins; and (iii) platelet activation
tendencies by flow cytometry. Hematologic parameters
included white and red blood cell counts, hematocrit,
platelet count, platelet crit, and mean platelet volume.
Surface membrane proteins assessed in unstimulated
platelets included major adhesive glycoprotein complex-
es: integrin  αIIbb3 (CD41a, CD41b, CD61), GPIb-V-IX
(CD42a, CD42b), integrin α2b1 (CD29, CD49b), GPIV
(CD36), GPVI and the surface-expressed protein tyrosine
phosphatase (CD148). Platelet activation tendency (inte-
grin activation and α-granule secretion) was measured
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following stimulation via P2Y1/12 receptors (with ADP),
GPVI (CRP-XL), or the PAR1 thrombin receptor (TRAP) in
the presence of aspirin and apyrase (where appropriate),
to suppress autocrine-dependent secondary activation.
For these platelet traits, heat mapping of the scaled values
again showed major inter-individual differences (Figure
2C), similarly as previously described.23
Comparative analysis of high-throughput parameters
For systematic evaluation of the eight parameters of
thrombi formed on six microspots for the 94 subjects, we
performed a correlational analysis across all microspot and
parameter combinations. As shown in Figure 3A,B, the
majority of parameters tended to correlate positively per
microspot, suggesting a 'thrombus profile' represented by
multiple parameters (median P values for all 6 microspots
High-throughput elucidation of thrombus formation
haematologica | 2019; 104(6) 1259
Figure 1. Microscopic imaging of platelet thrombus formation on six different
microspots and variability analysis. (A) Representative images after flow of whole
blood from a representative healthy subject over series of microspots M1-6 (com-
position as indicated). For the brightfield images, scored values are indicated for
parameters P3 (thrombus morphological score), P4 (thrombus multilayer score),
and P5 (thrombus contraction score). Bars, 20 μm. The definition of all parame-
ters is given in Table 1. (B) Three separate blood samples from ten healthy sub-
jects (cohort 1), taken at intervals of 2-4 weeks, were used to assess thrombus
formation on microspots M1, M2, and M6. Intra- and inter-individual coefficients
of variance (CV) are plotted per microspot and parameter. PS: phosphatidylserine.
B
A
5.22 x 10-5). Furthermore, positive correlations were also
present across multiple microspots. For instance, parame-
ters P2-5 (indicative of thrombus morphology and platelet
aggregation) correlated between M1 (collagen I) or M2
(collagen III) with M4 [GFOGER-(GPO)n + VWF-BP] and
M5 (rhodocytin + VWF-BP), i.e. all GPVI- and CLEC-2-
activating surfaces (P2-5; median P values 4.39 x 10-22).
Furthermore, several parameters (P2-8) correlated
between M2 (collagen III) and M3 (laminin + VWF,
P=0.44-1.04 x 10-11). Typically, parameters for microspot
M6 (fibrinogen + VWF-BP) showed no more than poor
correlation with those of other surfaces.
Multiparameter correlation and regression analysis were
also performed to compare subjects’ age and sex, hemato-
logic data, platelet glycoprotein expression levels and ago-
nist-induced platelet activation markers by flow cytome-
try. The interaction matrices displayed in Figure 3C,D
show the expected correlation of sex (much stronger than
age) with red blood cell and platelet counts (P<0.014), but
not with other traits. Subjects’ age correlated weakly with
J.P. Van Geffen et al.
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Figure 2. Inter-subject differences in platelet thrombus formation and other
platelet traits. (A) Using blood samples from 94 genotyped healthy subjects
(cohort 2), parameters of thrombus formation were assessed on microspots M1-
6. Duplicate samples were analyzed for ten of these subjects. The ratios of inter-
versus intra-individual coefficients of variance per parameter and microspot are
shown. (B) Heatmap of normalized parameters per microspot and per subject
(rows). Scaling of 0-10 was performed per parameter across all surfaces. (C)
Heatmap of additional platelet traits of the cohort of 94 subjects (scaling 0-10).
Hematologic variables: white blood cell count (WBC), red blood cell count (RBC),
hematocrit (HCT), platelet count (PLT), platelet crit (PCT = count x size), mean
platelet volume (MPV); platelet glycoprotein expression (integrin αIIbb3: CD41a,
CD41b, CD61; GPIb-V-IX: CD42a, CD42b; integrin α2b1: CD29, CD49b; CD36;
GPVI; CD148). In addition, activation markers of unstimulated, ADP-, CRP-XL- or
TRAP-stimulated platelets (A1-4), regarding integrin αIIbb3 activation (Int) and
secretion (P-selectin expression, Sec). For details of coding of microspots (M),
parameters (P) and activation markers (A), see Table 1. Raw data are provided
in Online Supplementary Data File 1A-C.
A B
C
platelet integrin activation. As required, red blood cell
count versus hematocrit, and platelet count versus platelet
crit (i.e. count x platelet size), were highly dependent vari-
ables (P<5.67 x 10-14). Platelet size (mean platelet volume)
correlated positively with the expression levels of surface
glycoproteins (P=0.03-1.92 x 10-14). In addition, the major-
ity of surface protein expression levels correlated signifi-
cantly with the components of glycoprotein complexes,
integrin αIIbb3 (CD41a, CD41b, CD61), GPIb-V-IX (CD42a,
CD42b) and integrin α2b1 (CD29, CD49b) (P=0.012-6.84 x
10-11). The exception was GPVI, which showed a lower
level of correlation with other glycoproteins.
Regression analysis of the markers of agonist-induced
platelet activation identified associations between integrin
High-throughput elucidation of thrombus formation
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Figure 3. Interactions between parameters of thrombus formation, hematology, platelet surface proteins and activation markers. For 94 genotyped healthy subjects
(cohort 2), multiple quantitative traits of thrombus formation, blood cell and platelet parameters, and platelet activation tendency were compared by regression analy-
sis. For coding of microspots (M), parameters (P) and activation markers (A), see Table 1. Other abbreviations are explained in Figure 2. (A, B) Correlation matrices for
parameters of thrombus formation. (A) Heat mapped –log P values, in which dark colors indicate highly significant correlations (white offset at P=0.05). (B) Heat
mapped Pearson correlation coefficients R, in which dark colors indicate high positive or negative correlations. (C, D) Correlation matrices for age, sex and platelet
quantitative traits (hematology variables, platelet glycoprotein expression levels and platelet activation markers). (C) Heat mapped –log P values, with colors as in panel
A. (D) Heat mapped Pearson correlation coefficients R, with colors as in panel C. Full statistical data are provided in Online Supplementary Data File 2A-D.
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activation and secretion in response to either ADP (A2) or
CRP-XL (A3) and, to a lesser extent, in response to TRAP
(A4) (Figure 3C,D). A clear relationship was present
between GPVI expression level and CRP-XL-induced acti-
vation markers (P=0.010 for integrin activation; P<0.0001
for secretion). Furthermore, except for TRAP-induced
secretion, all platelet activation markers were associated
with glycoprotein expression levels (median P=0.010) and,
to a certain extent, with platelet size. Taken together,
these results pointed to a subject-dependent component of
platelet size and activation, independent of the type of
agonist.
Comparative analysis of parameters of thrombus 
formation with other platelet traits
Principle component analysis (PCA), using the dataset of
94 subjects, was performed to further analyze the relation-
ships between the parameters of thrombus formation and
measured platelet quantitative traits. As a way to visualize
the results, the relative contributions of components 1 and
2 (C1, C2) were heat mapped for each of the microspots
and parameters. The resulting heatmaps (Figure 4) can be
read as indicating the parameters of thrombus formation
that tend to cluster together per component (in dark
color), when compared to other sets of variables.
PCA was first applied to compare parameters P1-8 for
each microspot with subjects’ age and sex (Figure 4A).
Component 1 (91.1%) showed a high correlation for all
microspots regarding the parameters P1 (platelet adhe-
sion) and P2-5 (collectively reflecting platelet aggregation
and thrombus morphology). Neither age nor sex con-
tributed to this component. Component 2 (1.5%) showed
a cluster of the platelet activation parameters P6-8 (proco-
agulant activity, secretion and integrin activation). Only
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Figure 4. Principal component analysis to reveal correlations between variables of thrombus formation and quantitative platelet traits. Principle component analy-
ses (PCA) of mean centered data from 94 healthy subjects (cohort 2), after univariate scaling as represented in Figure 2B,C. In order to reveal patterns of jointly con-
tributing factors to thrombus formation, scaled data from six microspots (M1-6) and eight parameters (P1-8) were combined in a PCA with sets of other variables
from the 94 subjects. Heatmaps show relative contributions of each of the parameters to the first two components, C1 and C2. For coding of microspots (M), param-
eters (P), and platelet activation markers (A), see Table 1. (A) PCA of the M × P matrix in combination with subjects’ age and sex. (B) PCA combined with hematologic
variables. (C) PCA combined with glycoprotein surface expression levels. (D) PCA combined with integrin αIIbb3 activation and secretion markers of agonist-stimulated
platelets. (E) PCA of only activation markers of agonist-stimulated platelets with glycoprotein surface expression levels. Color bars of relative contributions to C1 and
C2, ranging from 0 to 1. White boxes indicate no relation, while dark red boxes indicate a large contribution for the indicated parameters. Raw data are presented
in Online Supplementary Data File 2E.
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for microspot M3, did the subjects’ age, but not sex con-
tribute to component 2. Together, these results underscore
the earlier conclusion that parameters of platelet aggrega-
tion across microspots covariate.
Combined PCA of microspot parameters and hemato-
logic parameters (Figure 4B) resulted in a similar configu-
ration of component 1 (97.5%) as above, with in particular
high contributions of microspots M1-6 for P2-5. Platelet
count and platelet crit appeared in component 1 for
microspots M1-2, while these variables contributed to
component 2 (1.1%) for M3-6.
Combined PCA of microspot parameters and glycopro-
tein expression levels (Figure 4C) revealed a marked con-
tribution of most CD variables (although not of CD36) to
the first component (95.5%) regarding M1, M2 and M6,
suggesting that these expression levels were relevant to
thrombus formation on these microspots. Component 2
(0.8%) contained most of the glycoprotein expression lev-
els, particularly on M3 and M5 spots.
The combined PCA of microspot parameters with ago-
nist-induced platelet secretion and integrin activation
(Figure 4D) revealed a component 1 (89.0%), again show-
ing large contributions for M1-5 on parameters P1-5
(platelet adhesion, aggregation and thrombus morpholo-
gy). For microspot M6, component 1 also included the
platelet activation markers (A2-4, i.e., ADP, CRP-XL and
TRAP). Interestingly, component 2 (1.9%) revealed large
contributions of the platelet activation parameters on all
other microspots M1-5. These results suggested that
microspot M6 (VWF-BP + fibrinogen) is the most sensitive
to variation in common agonist-induced platelet activa-
tion traits, regardless of the agonist. A final PCA, combin-
ing glycoprotein expression markers with platelet activa-
tion markers, revealed strong correlations for the variables
linked to integrin αIIbb3 (Figure 4E).
Together, these results suggested that a considerable
part of the variability in thrombus outcomes between the
94 subjects was linked, in a surface-dependent way, to
hematologic traits (platelet count and crit), expression pat-
terns of glycoproteins and to agonist-induced secretion
and integrin αIIbb3 activation. Another part seemed to be
linked, across surfaces, to platelet aggregation and throm-
bus morphology.
Prediction models of platelet traits contributing 
to variation in thrombus formation
Based on the PCA, predictive models were built to iden-
tify the quantitative platelet traits that correlate with
thrombus formation parameters. In a first set of partial
least squares (PLS) models, we aimed to find the covari-
ance between the individual thrombus parameters and the
other platelet parameters. By predicting one variable of
the thrombus microspot - parameters matrix at a time, 14
(of 48) parameters had a reduction in the mean square
error of prediction, meaning that they could be predicted
more accurately than just using the mean (in cross valida-
tion). Eleven of the 14 models appeared to be robust (sin-
gle component, or improvement with an additional com-
ponent). Most of these models captured a limited amount
of the variation, although, for parameter P1, three models
(M4P1, M5P1, M2P7) predicted >5% (6-11%) of the total
variation (Figure 5A). This analysis explained a small part
of the variance, although with a focus on platelet adhesion
(P1) across the surfaces. Given the limited biological
insight of this effort, additional modeling was performed.
Since thrombus formation on three out of the six
microspots (M1, M2, M4) was GPVI-dependent, addition-
al prediction models were made to relate the values of
GPVI-induced integrin αIIbb3 activation (A3-Int) and secre-
tion (A3-Sec) to the thrombus parameters. All models
were checked by leaving-one-out cross-validations. To
predict GPVI-induced integrin activation, an orthogonal
PLS model was built with two components. This resulted
in a b matrix for each of the microspots and parameters
(Figure 5Bi). For the collagen microspots (M1-2), parame-
ters of platelet adhesion and activation (P1, P6-7) gave a
positive weight to the prediction, as well as the majority
of parameters of M6 (VWF-BP + fibrinogen). Interestingly,
for the strongest GPVI-dependent surfaces (M1, M4),
parameters determining platelet aggregation under flow
(P2-5, P8) weighed negatively on the prediction.
Concerning GPVI-induced secretion, the most suitable
PLS model had a single principal component. The resulting
b matrix was similar to that predicting GPVI-induced inte-
grin activation, albeit with more negative predictive
weights for some M5-6 parameters (Figure 5Bii). Taken
together, this analysis of the collagen surfaces indicates a
positive relationship between GPVI-induced platelet inte-
grin activation/secretion (assessed by flow cytometry) and
platelet adhesion and activation in a thrombus.
Prediction of genetic variants of platelet proteins 
associated with variation in thrombus formation
Genome-wide association studies have identified sever-
al hundreds of genetic variants associated with quantita-
tive platelets traits.16 Epigenetic mapping has revealed that
many of these variants are regulatory and lie within super-
enhancer regions that are implicated in megakaryocyte
differentiation and platelet production.20 For three variants
associated with platelet traits, we analyzed whether these
were also associated with thrombus formation parame-
ters. Univariate linear regression analysis for the whole M-
P matrix was used to identify associations with the fol-
lowing single nucleotide variants: rs1613662 (GP6), rs3557
(FCER1G) and rs2363877 (VWF-CD9) (Figure 5C).
The single nucleotide variant rs1613662 is a non-syn-
onymous variant in the GP6 gene, while rs3557 is located
in the 3’ untranslated region of FCER1G (Fcγ receptor
chain, a co-receptor of GPVI) in a megakaryocytic super-
enhancer region. Subjects carrying the major allele of
either variant (rs1613662, AA; and rs3557, TT) have high-
er levels of platelet GPVI, and higher CRP-XL-induced
platelet activation.20 For the present data set, regression
analysis indicated inter-allelic differences, in the same
direction, in thrombus formation parameters at the colla-
gen surfaces M1-2 for P1 (platelet adhesion) with
rs1613662 (Figure 5Ci, ii). In addition, for rs3557 we iden-
tified associations at M1-2 and M4, i.e., the other GPVI-
dependent surface, regarding P8 (integrin activation).
Unexpectedly, alleles of both variants were also associated
with parameters at the CLEC-2-dependent microspot M5
(VWF-BP + rhodocytin).
The variant rs2363877 is located in a megakaryocyte-
specific super-enhancer site that interacts with the gene
promoters of VWF and CD9. This single nucleotide vari-
ant is linked to opposite changes in expression levels of
platelet-stored VWF and the surface levels of the
tetraspanin CD9.20 Here an allelic association was identi-
fied at microspot M5 for secretion (P7) (Figure 5Ciii).
Trends were also seen for platelet adhesion (P1) at the
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microspots M1 and M5. Interestingly, the rs2363877 allele
linked to increased thrombus parameters at M1 was also
associated with high CD9 levels, but low platelet VWF
levels.24 Altogether, these analyses identified novel varia-
tion in platelet thrombus parameters associated with GP6
signaling for GPVI/collagen-dependent platelet adhesion
(P1) and activation (P6-8).
Thrombus signature based on parameters
of platelet aggregation
To further evaluate the inter-subject differences in
thrombus formation, blood was obtained from three
patients with Glanzmann thrombasthenia (confirmed
mutations in ITG2B, defective integrin αIIbb3 expression),
two patients with delta storage pool disease (reduced
dense granule secretion), and three healthy day-control
subjects. Application of the multiparameter test with the
patients’ blood samples revealed identifiable patterns of
altered thrombus formation on all microspots (raw data in
Data File 1D). Interestingly, the altered patterns seen with
the three Glanzmann samples (Online Supplementary Figure
S1A-C) reinforced the earlier PCA results that, across
microspots, the values of P2-5 (and to a lesser extent P8)
tended to cluster. All of these parameters relate to platelet
aggregation and contraction, i.e. platelet functions known
to be impaired in these patients. For the patients with stor-
age pool disease, similar but less striking patterns of
changes were observed (Online Supplementary Figure
S1D,E).
Subsequently, we determined whether this cluster of
parameters also provides information on the thrombus
signature for healthy subjects. The summative scaled
value Σ(P2-5, P8) was calculated per microspot and for all
microspots. Supervised clustering, ranking the 94 subjects
according to this summation, did indeed point to patterns
of high and low platelet aggregation, which extended over
multiple microspots (Figure 6A). For the three Glanzmann
patients, these summative values were very low, as
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Figure 5. Prediction models explaining variation in thrombus formation. (A) Partial
least squares (PLS) models determining the covariance for each of the individual
thrombus parameters (M1-M6, P1-P8) and all other platelet traits. Fourteen (from
48) parameters showed a relevant prediction, capturing 0.2-10.9% (blue color inten-
sity) of the variation. (B) Beta matrix per individual parameter for the PLS models of
GPVI-induced platelet activation (unit variance scaled, mean centered data): (i) GPVI-
induced αIIbb3 activation (A3-Int, 2 components orthogonal PLS); (ii) GPVI-induced
secretion (A3-Sec, 1 component PLS). Positive and negative weights are indicated by
different colors. (C) Matrix of significance per parameter (quantile normalized linear
regression, and likelihood ratio test per allelic score), expressed as P values, for the
following genetic variants: (i) GP6, rs1613662 (AA, GA, GG; n = 63, 29, 1); (ii)
FCER1G, rs3557 (TT, TG, GG; n = 67, 24, 2); (iii) VWF-CD9, rs2363877 (GG, GA, AA;




expected. For the two patients with storage pool disease,
these values appeared to be in the lower ranges of normal.
To further assess the subject-dependent component of
this thrombus signature, we evaluated the intra- and inter-
individual variations in Σ(P2-5, P8). This analysis indicated
2 to 5 times higher inter-individual coefficients of varia-
tion (Figure 6B). Interestingly, this measure of the throm-
bus signature was not related to GPVI expression of GPVI-
induced platelet responses, thus pointing to other factors
determining the platelet aggregation profile under flow
conditions.
Discussion
Multiparameter assessment of thrombus formation
using microfluidic assays has proven to be relevant for the
assessment of platelet dysfunction in patients with differ-
ent bleeding diatheses.7-9 In the present study, we further
developed this technique to assess the sources of variabil-
ity in thrombus formation between individuals with nor-
mal hemostasis. We evaluated platelet quantitative traits
as well as thrombus formation in a cohort of 94 genetical-
ly defined healthy subjects. Regression analysis identified
an overall strong correlation between most parameters per
microspot surface. When comparing different microspots,
especially parameters of platelet aggregation and throm-
bus morphology (P2-5) correlated with each other for
GPVI- and CLEC-2-activating surfaces (M1-2, M4-5).
These parameters appear to describe subject-dependent
differences in thrombus formation or thrombus signature,
such as was also deduced from strong alterations in these
parameters in blood from patients with Glanzmann
thrombasthenia. Comparative matrices of other traits did
not reveal age or sex as determinants of thrombus forma-
tion, in accordance with previous analyses.20,25,26 A clear
relation was however observed between GPVI expression
levels and CRP-XL-induced platelet activation markers,
which is in agreement with an early report.27
Several PCA were applied to compare the matrix of
thrombus formation parameters with other platelet traits.
An effect of platelet count and crit was seen for thrombus
formation on collagen-containing microspots (M1-2), in
agreement with an earlier conclusion that platelet count is
a regulatory determinant of collagen-dependent thrombus
formation.9 Regression analysis confirmed the predicted
associations between mean platelet volume and expres-
sion levels of most platelet membrane glycoproteins. In
addition, associations were seen between platelet activa-
tion markers after ADP, CRP-XL or TRAP activation and
glycoprotein expression levels.
A PCA of thrombus parameters plus glycoprotein
expression levels revealed marked contributions of most
CD markers to the first component (95.5%) for M1, M2
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Figure 6. Identification of thrombus signatures
across microspots. (A) Supervised clustering of
thrombus parameters P2-5 and P8 for microspots
M1-6, aligned as indicated. Ranking of data from
94 subjects (cohort 2), patients with storage pool
disease (SPD1-2) or Glanzmann thrombasthenia
(GT1-3) and day-controls (C1-3) was according to
the sum of normalized thrombus parameters of all
surfaces Σ(P2-5, P8). Order of subjects (compare
Figure 1B): 92, 49, 33, 4, 57, 35, 9, 19, 6, 8, 15,
24, 78, 50, 16, 42, 20, 65, C3, 72, 41, 44, 76, 71,
18, 25, 26, 52, 40, 10, C2, 51, 5, 12, 28, 29, 36,
67, 23, 32, 38, 2, 88, 17, 54, 59, 89, 81, 60, 80,
11, 82, 73, 79, 69, 55, 87, 48, 47, 66, 53, 7, 70,
93, 64, 1, 45, 46, 30, 91, 3, 94, 77, 68, 43, 34,
86, 62, 58, 37, 75, 63, 27, 39, 83,  C1, 22, 85,
90, 21, 13, 31, 61, 74, 84, 56, SPD1, SPD2, GT1,
GT2, GT3. Note the overall consistency of the
platelet aggregation-linked parameters (P2-5, P8)
per subject. (B) Intra- and inter-individual coeffi-
cients of variance  (CV) of summative value Σ(P2-
5, P8) per microspot (cohort 2), together with




and M6, suggesting that these expression levels deter-
mine, at least partially, thrombus formation on these
microspots. The PCA with platelet activation markers did
not reveal clear links with thrombus parameters, except
for the weakest surface M6. Together with the relatively
high intra-subject variance of this surface, this finding sug-
gests that M6 parameters detect small changes in the acti-
vation tendency of platelets, possibly related to the quality
of the blood sample.
A PLS prediction model was developed to assess the
extent to which the platelet traits can explain the meas-
ured inter-subject variation in thrombus formation.
Results revealed a limited predictability for platelet adhe-
sion (P1) at various microspots (M4-5). Overall, 1-2% of
the variance could be predicted in this way, likely because
of the multivariate and multidirectional nature of these
platelet traits. As a more targeted and powerful approach,
regression models were built to predict the M-P matrices
from subject-dependent values of GPVI-induced integrin
activation and secretion. As expected, the CRP-XL-
induced integrin activation and secretion measures were
positively associated with GPVI-dependent microspot
(M1-2) parameters of platelet adhesion and activation (P1,
P7). A negatively weighted prediction was seen for param-
eters of M4-5 (VWF-BP + GFOGER-(GPO)n; VWF-BP +
rhodocytin), possibly because of the relatively large roles
of α2b1 and CLEC-2, respectively, on these surfaces.
Regarding GPVI-induced integrin activation, a positively
weighted prediction was seen for thrombi on the αIIbb3-
dependent microspot M6, suggesting that the variation on
this surface had different causes.
Regression analysis also indicated associations for single
nucleotide variants that are linked to alterations in platelet
size or GPVI-induced platelet activation.20,27 For two single
nucleotide variants linked to GPVI expression, rs1613662
(GP6) and rs3557 (super-enhancer for FCER1G), allelic
associations were identified with the GPVI-dependent
microspots (M1-2, M4) for platelet adhesion (P1) and
platelet activation (P8, integrin activation) parameters. In
addition, single nucleotide variant associations were
observed for thrombus formation on the CLEC-2-depen-
dent microspot M5, for unclear reasons. Other authors
have used microfluidics assays to show that subject-
dependent differences in platelet calcium fluxes contribute
to a variation in collagen-dependent thrombus forma-
tion.28 This work supports our findings of the presence of
a subject-dependent factor in GPVI-induced platelet acti-
vation and thrombus formation on collagen surfaces.
In contrast, no associations were seen for the single
nucleotide variant of the VWF-CD9 locus. Plasma levels of
VWF are known to determine the thrombus outcome in
flow assays.29 However, the variant rs2363877 only modi-
fies platelet-accumulated VWF, rather than plasma VWF.20
A limitation of our study is that, despite the measure-
ment of over 70 different blood and platelet traits, the
number of healthy subjects was restricted to 94, thus lim-
iting the statistical power and the precise assignment of
the meaning of all individual parameters. Further work in
larger cohorts of healthy subjects, and in patients with
known platelet and plasma disorders, will add to the char-
acterization of many of these parameters.
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